Save up -80% on Pembrolizumab

Note: this is a drug discount program, not an insurance plan.

RX BIN: 015558
RX PCN: HT
Group ID: DDN6600
Card Holder ID: DDN6600

Pharmacists and Patients support.

2018 Price of Keytruda

$6.711

50mg

* price without discount in nearest pharmacy. Price may vary.

Claim your free Pembrolizumab discount card

We offer free Pembrolizumab coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Pembrolizumab every time. What are you waiting for? Claim your prescription drug card now!

Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time

Pembrolizumab volume of distribution

About RX24Drugs

Discount Cards 16,000+

Clients Benefit 29%

Total savings $4,735,080

What is Pembrolizumab

Pembrolizumab is an antibody drug that targets the cell surface receptor programmed cell death protein 1 (PD-1) found on T cells. By preventing the binding of its ligands (PD-L1 and PD-L2), pembrolizumab induces an antitumor immune response. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Its use is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following therapy with ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Due to its success in clinical trials, pembrolizumab was approved early to allow quick patient access and was given breakthrough therapy and orphan drug designation. Pembrolizumab (as Keytruda) was approved by the U.S. Food and Drug Administration to treat advanced cases of the most common type of lung malignancy, non-small cell lung cancer (NSCLC) on Oct. 2, 2015.

Pembrolizumab mechanism of action

Pembrolizumab is an antibody drug that targets the cell surface receptor programmed cell death protein 1 (PD-1) found on T cells. By preventing the binding of its ligands (PD-L1 and PD-L2), pembrolizumab induces an antitumor immune response. Upregulation of PD-1 ligands is a mechanism for tumours to evade antitumor immune response; when PD-1 binds its ligand, the T cell receives an inhibitory signal leading to T cell anergy and blockade of anti tumour immune response. Instead of directly targeting tumor tissue to induce tumor cell death, pembrolizumab acts as a checkpoint inhibitor to stimulate immune responses to eliminate cancer cells.

Dosage forms of Pembrolizumab

DrugDosageQuantityPrice
Keytruda50mgvial$6.711
Prescription Generics

false

International Brands

Keytruda

Synonyms

Manufacturers

Merck Canada Inc

CAS number

1374853-91-4

UNII

DPT0O3T46P

State

solid

Affected organisms

Humans and other mammals

Indication of Pembrolizumab

For the treatment of patients with unresectable or metastatic melanoma and disease progression following therapy with ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. It is also for the treatment of patients with metastatic NSCLC (non-small cell lung cancer) whose tumors express PD-L1 (as determined by an approved test) and who have disease progression on or after platinum-containing chemotherapy.

Toxicity of Pembrolizumab

Since therapy with pembrolizumab induces tumour regression by stimulation of immune responses, side effects may be caused by activating potentially self-reactive T cells. This includes immune-mediated pneumonitis, colitis, hypophysitis, nephritis and renal failure, hyperthyroidism and hypothyroidism, and hepatitis. Other adverse events such as myasthenic syndrome, optic neuritis, uveitis, arthritis, pancreatitis, partial seizures, and rhabdomnyolysis were reported to occur in less than 1% of patients during clinical trials. Female patients are advised to use highly effective contraception during and for 4 months following treatment due to the risk of fetal harm.

RX24 Drugs Disclaimer: before buying a Pembrolizumab on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.

Get lower price on Pembrolizumab now!